Lancet Haematology

Scope & Guideline

Advancing hematology through innovative research.

Introduction

Immerse yourself in the scholarly insights of Lancet Haematology with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN2352-3026
PublisherELSEVIER SCI LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2014 to 2024
AbbreviationLANCET HAEMATOL / Lancet Haematol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address125 London Wall, London EC2Y 5AS, ENGLAND

Aims and Scopes

Lancet Haematology is dedicated to advancing the field of hematology through the publication of high-quality research articles that encompass a wide range of topics related to blood disorders and treatments. The journal aims to provide a platform for innovative research and clinical practices that can improve patient outcomes and healthcare strategies in hematology.
  1. Translational Research in Hematology:
    The journal emphasizes the importance of translational research that bridges the gap between laboratory findings and clinical applications, focusing on novel therapies and treatment strategies for hematological malignancies.
  2. Clinical Trials and Evidence-Based Medicine:
    Lancet Haematology publishes articles detailing results from clinical trials, systematic reviews, and meta-analyses that contribute to evidence-based practices in hematology, thereby aiding clinicians in making informed treatment decisions.
  3. Innovative Therapies and Treatment Protocols:
    The journal highlights advancements in the development and application of innovative therapies, such as CAR T-cell therapy, immunotherapy, and gene therapy, aimed at improving patient outcomes in various hematological conditions.
  4. Patient-Centered Care and Quality of Life:
    Research focusing on the quality of life and patient-reported outcomes in individuals with blood disorders is a key area of interest, reflecting the journal's commitment to patient-centered care.
  5. Global Health Perspectives in Hematology:
    Lancet Haematology addresses the global burden of hematological diseases, particularly in low- and middle-income countries, focusing on strategies to improve access to care and treatment equity.
The journal has experienced a notable evolution in its research themes, with several emerging topics gaining prominence. These trends reflect the dynamic nature of hematology and the ongoing quest for improved patient care and treatment options.
  1. Gene Therapy and Genetic Engineering:
    There is a rising trend in publications related to gene therapy and genetic engineering, reflecting advancements in techniques and their potential applications in treating inherited blood disorders and malignancies.
  2. Immunotherapy and CAR T-Cell Therapies:
    Research on immunotherapy, particularly CAR T-cell therapies, is increasingly prevalent, indicating a significant shift towards leveraging the immune system in combating hematological malignancies.
  3. Social Determinants of Health:
    A growing emphasis on the social determinants of health and their impact on patient outcomes in hematology is emerging, highlighting the importance of addressing disparities in access to care and treatment.
  4. Patient-Centric Research and Quality of Life:
    An increasing number of studies focus on patient-reported outcomes and quality of life assessments, emphasizing the importance of patient perspectives in treatment decision-making and care strategies.
  5. Environmental Impact of Hematological Care:
    Emerging research addressing the environmental impact of hematology practices and strategies for sustainability is becoming more prominent, reflecting a broader awareness of healthcare's ecological footprint.

Declining or Waning

While the journal continues to address a broad spectrum of topics, certain themes have shown a decline in frequency or prominence in recent publications. This may reflect shifts in research focus or changes in clinical practice within the field of hematology.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decrease in publications centered on traditional chemotherapy approaches for hematological malignancies, as the field increasingly shifts towards targeted therapies and immunotherapies.
  2. Single-Agent Therapy Studies:
    The focus on single-agent therapies is waning as combination therapies and multi-modal treatment strategies gain traction, indicating a shift towards more comprehensive treatment regimens.
  3. Basic Science Research in Hematology:
    Research articles that solely focus on basic science without direct clinical application are becoming less common, as the journal prioritizes studies with immediate relevance to clinical practice.
  4. Hematology in Pregnancy:
    Although still important, there has been a decrease in the volume of research specifically addressing hematological conditions during pregnancy, as the field's focus broadens to encompass a wider range of patient populations.

Similar Journals

BLOOD REVIEWS

Fostering innovation in the science of blood.
Publisher: CHURCHILL LIVINGSTONEISSN: 0268-960XFrequency: 6 issues/year

BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.

Hematology-American Society of Hematology Education Program

Unlocking Insights for Hematology Professionals
Publisher: AMER SOC HEMATOLOGYISSN: 1520-4391Frequency: 1 issue/year

Hematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.

Journal of Hematology

Pioneering Discoveries in Blood Health
Publisher: ELMER PRESS INCISSN: 1927-1212Frequency: 4 issues/year

The Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.

Hematology Reports

Fostering collaboration in hematological research.
Publisher: MDPIISSN: 2038-8322Frequency: 4 issues/year

Hematology Reports is an esteemed academic journal in the field of hematology, dedicated to advancing the understanding of blood disorders and their treatment. Published by MDPI, a leading Swiss publisher known for its commitment to open access since 2009, this journal provides a valuable platform for researchers and healthcare professionals to disseminate innovative findings and foster collaboration within the academic community. The journal features an array of articles ranging from clinical studies to laboratory research, and is indexed in Scopus, where it currently holds a rank of 113 out of 137 in the Medicine - Hematology category, placing it in the 17th percentile. As an open-access journal, Hematology Reports ensures that critical research is accessible to a global audience, supporting the dissemination of knowledge that has the potential to improve patient outcomes. This journal is an essential resource for those engaged in the study and treatment of hematological conditions, encouraging dialogue and the exchange of ideas to enhance clinical practices.

BONE MARROW TRANSPLANTATION

Advancing the Frontiers of Transplantation Science.
Publisher: SPRINGERNATUREISSN: 0268-3369Frequency: 12 issues/year

BONE MARROW TRANSPLANTATION, published by SpringerNature, stands as a leading journal in the fields of Hematology and Transplantation, as evidenced by its recognition in the Q1 category for both disciplines according to 2023 rankings. With an impressive impact factor and notable Scopus rankings—7th out of 54 in Medicine Transplantation and 25th out of 137 in Medicine Hematology—this journal is instrumental for researchers and professionals dedicated to advancements in bone marrow transplantation practices and research. Established in 1986, the journal publishes original research, clinical studies, and reviews that push the boundaries of current knowledge, making it essential reading for those looking to stay abreast of the latest developments in the field. Although offering limited Open Access options, BONE MARROW TRANSPLANTATION reaches a broad audience and furthers a global dialogue on best practices and innovative approaches in transplantation medicine. Its address in London, UK positions it at the heart of international research collaboration, fostering connections among scientists, clinicians, and students alike.

ANNALS OF HEMATOLOGY

Exploring breakthroughs in blood disorders and treatments.
Publisher: SPRINGERISSN: 0939-5555Frequency: 12 issues/year

ANNALS OF HEMATOLOGY, published by Springer in Germany, stands as a premier platform for advancing knowledge in the field of hematology and medicine at large. With a significant impact factor and recognized rankings—Q2 in Hematology and Q1 in Medicine (miscellaneous) as of 2023—this journal is pivotal for researchers, clinicians, and students who are keen on exploring the latest developments in blood disorders, treatments, and innovative methodologies. Its broad scope encompasses original research, reviews, and discussions that aim to foster interdisciplinary dialogue, ensuring that the latest findings and theories are accessible to the scientific community. Although not an open-access journal, its rigorous peer-review process guarantees high-quality contributions, thereby solidifying its reputation as a vital resource in the hematological field. Founded in 1991, the ANNALS OF HEMATOLOGY continues to evolve, converging invaluable insights from both basic and clinical research until 2024. For those dedicated to improving patient outcomes and advancing hematological science, this journal remains an essential reference.

Iraqi Journal of Hematology

Innovative Insights for Blood Health
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2072-8069Frequency: 2 issues/year

Iraqi Journal of Hematology is a prominent peer-reviewed open-access journal dedicated to advancing the field of hematology. Published by Wolters Kluwer Medknow Publications, this journal provides a platform for researchers, professionals, and students to share cutting-edge findings and developments in various aspects of hematology, including blood diseases, diagnostics, and innovative treatments. Since its transition to open access in 2016, the journal has significantly increased its reach, allowing for wider dissemination of critical research to a global audience. With an ISSN of 2072-8069 and an E-ISSN of 2543-2702, the Iraqi Journal of Hematology strives to adhere to the highest scholarly standards and plays a vital role in the ongoing discourse in hematological research. Researchers are encouraged to contribute to this essential resource for the scientific community, contributing to the advancement of knowledge that ultimately improves patient care and treatment outcomes.

Turkish Journal of Hematology

Championing open access to vital hematology knowledge.
Publisher: GALENOS PUBL HOUSEISSN: 1300-7777Frequency: 4 issues/year

Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.

Blood Cancer Discovery

Driving Collaborative Efforts for Better Patient Outcomes
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2643-3230Frequency: 6 issues/year

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

BRITISH JOURNAL OF HAEMATOLOGY

Shaping the Future of Hematological Science
Publisher: WILEYISSN: 0007-1048Frequency: 23 issues/year

British Journal of Haematology, published by Wiley, is a leading journal in the field of hematology, with an impressive impact factor reflecting its significance in the medical research community. Established in 1955, the journal has consistently contributed to advancing knowledge in hematology, currently holding a prestigious Q1 ranking in the Scopus category of Hematology, placing it in the top 18% of the field. The journal encompasses a broad range of topics including clinical and laboratory aspects of blood disorders and hematological malignancies, making it an essential resource for hematologists, researchers, and healthcare professionals. With its commitment to publishing top-tier research and clinical studies, the British Journal of Haematology plays a critical role in shaping treatment approaches and improving patient outcomes worldwide. Please note that this journal does not offer Open Access options, ensuring that published content is rigorously curated for quality and relevance.